Anne Tailleux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7865598/publications.pdf

Version: 2024-02-01

93 papers	6,433 citations	76322 40 h-index	69246 77 g-index
94 all docs	94 docs citations	94 times ranked	9563 citing authors

#	Article	IF	Citations
1	Apolipoprotein F is reduced in humans with steatosis and controls plasma triglycerideâ€rich lipoprotein metabolism. Hepatology, 2023, 77, 1287-1302.	7.3	3
2	Bile acids contribute to the development of non-alcoholic steatohepatitis in mice. JHEP Reports, 2022, 4, 100387.	4.9	28
3	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
4	Enterohepatic Takeda G-Protein Coupled Receptor 5 Agonism in Metabolic Dysfunction-Associated Fatty Liver Disease and Related Glucose Dysmetabolism. Nutrients, 2022, 14, 2707.	4.1	8
5	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	3.8	20
6	NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Reports, 2021, 3, 100222.	4.9	24
7	Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structureâ€“Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor. Journal of Medicinal Chemistry, 2021, 64, 1593-1610.	6.4	9
8	Multiple Selection Criteria for Probiotic Strains with High Potential for Obesity Management. Nutrients, 2021, 13, 713.	4.1	19
9	Characterization of one anastomosis gastric bypass and impact of biliary and common limbs on bile acid and postprandial glucose metabolism in a minipig model. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E772-E783.	3.5	8
10	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	3.7	77
11	Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metabolism, 2021, 33, 1483-1492.e10.	16.2	79
12	The ALGOVUE Clinical Trial: Effects of the Daily Consumption of Eggs Enriched with Lutein and Docosahexaenoic Acid on Plasma Composition and Macular Pigment Optical Density. Nutrients, 2021, 13, 3347.	4.1	9
13	Inflammationâ€induced cholestasis in cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 70-90.	7.3	24
14	Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System. Frontiers in Molecular Neuroscience, 2021, 14, 808603.	2.9	9
15	Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. Metabolism: Clinical and Experimental, 2020, 103, 154042.	3.4	21
16	Deletion of the nuclear receptor RORÎ± in macrophages does not modify the development of obesity, insulin resistance and NASH. Scientific Reports, 2020, 10, 21095.	3.3	6
17	Analysis of the association of MPO and MMP-9 with stroke severity and outcome. Neurology, 2020, 95, e97-e108.	1.1	42
18	The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. Scientific Reports, 2020, 10, 174.	3.3	45

#	Article	IF	Citations
19	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis â€“ Central role of macrophage scavenger receptor 1. Journal of Molecular and Cellular Cardiology, 2020, 139, 24-32.	1.9	26
20	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2311-2321.	3.6	39
21	Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1094-E1107.	3.5	6
22	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiology of Disease, 2019, 125, 14-22.	4.4	16
23	Hepatic PPARÎ± is critical in the metabolic adaptation to sepsis. Journal of Hepatology, 2019, 70, 963-973.	3.7	53
24	Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?. Current Opinion in Lipidology, 2019, 30, 244-254.	2.7	39
25	Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut, 2018, 67, 271-283.	12.1	150
26	Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. International Journal of Obesity, 2017, 41, 664-668.	3.4	21
27	Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2017, 152, 1679-1694.e3.	1.3	630
28	Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis, 2017, 257, 186-194.	0.8	17
29	Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance. Journal of Medicinal Chemistry, 2017, 60, 4185-4211.	6.4	48
30	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3783-3794.	3.6	78
31	Tau deletion promotes brain insulin resistance. Journal of Experimental Medicine, 2017, 214, 2257-2269.	8.5	158
32	Metabolic effects of bile acid sequestration. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 138-144.	2.3	9
33	Lipid-lowering drugs prevent neurovascular and cognitive consequences of cardiopulmonary bypass. Vascular Pharmacology, 2016, 80, 59-66.	2.1	11
34	Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. International Journal of Obesity, 2016, 40, 1260-1267.	3.4	61
35	Liver X Receptor Regulates Triglyceride Absorption Through Intestinal Down-regulation of Scavenger Receptor Class B, Type 1. Gastroenterology, 2016, 150, 650-658.	1.3	41
36	Bariatric surgery, lipoprotein metabolism and cardiovascular risk. Current Opinion in Lipidology, 2015, 26, 317-324.	2.7	15

#	Article	IF	Citations
37	The Sirt1 activator SRT3025 provides atheroprotection in Apoeâ^'/â^' mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. European Heart Journal, 2015, 36, 51-59.	2.2	117
38	Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2473-2478.	7.1	310
39	Rapid and Body Weightâ€"Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass. Circulation, 2015, 131, 871-881.	1.6	103
40	The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell Metabolism, 2015, 22, 418-426.	16.2	342
41	Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nature Communications, 2015, 6, 7629.	12.8	274
42	Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice. Transgenic Research, 2015, 24, 803-812.	2.4	8
43	Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology, 2014, 59, 2022-2033.	7.3	55
44	Impact of Endotoxin Challenge in Obese Pigs. Shock, 2014, 41, 546-553.	2.1	10
45	Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. Journal of Lipid Research, 2014, 55, 41-52.	4.2	15
46	Cdkn2a/p16Ink4a Regulates Fasting-Induced Hepatic Gluconeogenesis Through the PKA-CREB-PGC1Î± Pathway. Diabetes, 2014, 63, 3199-3209.	0.6	36
47	The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology, 2014, 60, 1593-1606.	7.3	116
48	Sox17 Regulates Liver Lipid Metabolism and Adaptation to Fasting. PLoS ONE, 2014, 9, e104925.	2.5	15
49	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013, 58, 1941-1952.	7.3	355
50	Long-term prognostic value of preprocedural adiponectin levels in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 4921-4924.	1.7	3
51	Normal HDLâ€"apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy. Metabolism: Clinical and Experimental, 2013, 62, 492-498.	3.4	8
52	Detrimental Effects of Diet-Induced Obesity on Ï„ Pathology Are Independent of Insulin Resistance in Ï„ Transgenic Mice. Diabetes, 2013, 62, 1681-1688.	0.6	88
53	Activation of intestinal peroxisome proliferator-activated receptor-Â increases high-density lipoprotein production. European Heart Journal, 2013, 34, 2566-2574.	2.2	44
54	Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. Journal of Lipid Research, 2013, 54, 1360-1368.	4.2	23

#	Article	IF	Citations
55	171. Critical Care Medicine, 2013, 41, A37.	0.9	1
56	Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits. Atherosclerosis, 2012, 222, 360-366.	0.8	11
57	Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 809-818.	2.4	229
58	Cellâ€derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?. Journal of Cellular and Molecular Medicine, 2012, 16, 1365-1376.	3.6	65
59	Bone Marrow p16INK4a-Deficiency Does Not Modulate Obesity, Glucose Homeostasis or Atherosclerosis Development. PLoS ONE, 2012, 7, e32440.	2.5	14
60	PPARÎ± activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis, 2011, 218, 69-76.	0.8	24
61	p16INK4a deficiency promotes IL-4â€“induced polarization and inhibits proinflammatory signaling in macrophages. Blood, 2011, 118, 2556-2566.	1.4	89
62	Overview of the Measurement of Lipids and Lipoproteins in Mice. Current Protocols in Mouse Biology, 2011, 1, 265-277.	1.2	2
63	Peroxisome Proliferatorâ€“Activated Receptor-Î± Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1573-1579.	2.4	66
64	Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPARÎ³ and LXRÎ± Pathways. Circulation Research, 2011, 108, 985-995.	4.5	318
65	Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1488-1495.	2.4	63
66	Morphologic and Electroretinographic Phenotype of SR-BI Knockout Mice after a Long-Term Atherogenic Diet. , 2009, 50, 3931.		35
67	Novel non-carboxylic acid retinoids: 1,2,4-Oxadiazol-5-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 489-492.	2.2	15
68	Niemannâ€“Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochemical and Biophysical Research Communications, 2006, 340, 1259-1263.	2.1	156
69	The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2731-2737.	2.4	69
70	Increased Susceptibility of Low-Density Lipoprotein to Ex Vivo Oxidation in Mice Transgenic for Human Apolipoprotein B Treated with 1 Melatonin-Related Compound Is Not Associated with Atherosclerosis Progression. Journal of Cardiovascular Pharmacology, 2005, 46, 241-249.	1.9	18
71	HOST GLUCOSE METABOLISM MEDIATES T4 AND IL-7 ACTION ON SCHISTOSOMA MANSONI DEVELOPMENT. Journal of Parasitology, 2005, 91, 737-744.	0.7	18
72	PPARÎ±, but not PPARÎ³, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1897-1902.	2.4	70

#	Article	IF	Citations
73	Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1737, 130-137.	2.4	20
74	Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends in Pharmacological Sciences, 2003, 24, 530-534.	8.7	26
75	Lipid Free Apolipoprotein E Binds to the Class B Type I Scavenger Receptor I (SR-BI) and Enhances Cholesteryl Ester Uptake from Lipoproteins. Journal of Biological Chemistry, 2002, 277, 36092-36099.	3.4	50
76	Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis, 2002, 164, 1-13.	0.8	126
77	Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochemical and Biophysical Research Communications, 2002, 293, 1114-1123.	2.1	31
78	Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation. Journal of Pineal Research, 2002, 33, 109-117.	7.4	25
79	Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Clinical Science, 2001, 100, 343-355.	4.3	9
80	Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Clinical Science, 2001, 100, 343.	4.3	8
81	Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11Î²-Hydroxysteroid Dehydrogenase Type 1 Null Mice. Journal of Biological Chemistry, 2001, 276, 41293-41300.	3.4	395
82	Peroxisome Proliferator-activated Receptor Î± Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil. Journal of Biological Chemistry, 2001, 276, 4634-4639.	3.4	70
83	Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2453-2458.	2.4	51
84	Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits. Biochemical and Biophysical Research Communications, 2000, 269, 232-236.	2.1	85
85	Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty. Clinica Chimica Acta, 2000, 299, 129-140.	1.1	12
86	3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Letters, 1999, 452, 160-164.	2.8	80
87	Cholesterol Efflux, Lecithinâ˜Cholesterol Acyltransferase Activity, and Pre-Î² Particle Formation by Serum from Human Apolipoprotein A-I and Apolipoprotein A-I/Apolipoprotein A-II Transgenic Mice Consistent with the Latter Being Less Effective for Reverse Cholesterol Transportâ€. Biochemistry, 1997, 36, 2243-2249.	2.5	66
88	Transgenic Rabbits Expressing Human Apolipoprotein A-I in the Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1424-1429.	2.4	55
89	Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-Iâ€“Transgenic Rabbits. Circulation, 1996, 94, 713-717.	1.6	184
90	A 700-bp fragment of the human antithrombin III promoter is sufficient to confer high, tissue-specific expression on human apolipoprotein A-II in transgenic mice. Gene, 1995, 156, 199-205.	2.2	17

#	Article	IF	Citations
91	Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Lipids and Lipid Metabolism, 1995, 1255, 31-38.	2.6	20
92	Tissue-specific Expression of the Human Gene for Lecithin: Cholesterol Acyltransferase in Transgenic Mice Alters Blood Lipids, Lipoproteins and Lipases towards a Less Atherogenic Profile. FEBS Journal, 1995, 230, 567-575.	0.2	53
93	Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients. Kidney International, 1993, 44, 1360-1365.	5.2	11